Legend Biotech (LEGN) Finished Goods (2022 - 2023)

Legend Biotech's (LEGN) quarterly Finished Goods came in at $4.0 million in Q3 2023, up 6.34% on a QoQ basis from $3.8 million in Q2 2023.

Legend Biotech (LEGN) Finished Goods (2022 - 2023) Analysis & Trends

Legend Biotech (LEGN) has 2 years of Finished Goods data on file, last reported at $4.0 million in Q3 2023.

Quarterly Finished Goods changed N/A year-over-year to $4.0 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $4.0 million (changed N/A YoY) and the FY2022 annual result came in at $2.7 million, changed N/A from the prior year.
Finished Goods improved to $4.0 million in Q3 2023, from $3.8 million in the prior quarter.
In the past five years, Finished Goods ranged from a high of $4.0 million in Q3 2023 to a low of $2.7 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Legend Biotech	3.95 Bn	3.27 Bn	251.50 Mn

Download Data